• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AVROBIO, Inc.

    < Previous 1 2 Next >
    AVROBIO and Tectonic Therapeutic Announce Merger
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Explore Strategic Alternatives
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Leadership Transition
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Share Comprehensive Gaucher Disease Program Update
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Participate in Four Upcoming Investor Conferences in September
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO to Participate in Two Upcoming Investor Conferences in August
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
    From AVROBIO, Inc.
    Via Business Wire
    Tickers AVRO
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.